ArticleFrontiers in public health2025

Cost-effectiveness analysis of second-generation androgen receptor antagonists for the treatment of metastatic hormone-sensitive prostate cancer.

Yang Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.